The clinical significance of circulating DSCAM-AS1 in patients with ER-positive breast cancer and construction of its competitive endogenous RNA network

Moradi, Mohammad‐Taher; Fallahi, Hossein; Rahimi, Zohreh

doi:10.1007/s11033-020-05841-5

Cited by 6 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, their advantages over other biomolecules, such as proteins and mRNAs, have been demonstrated [ 40 ], as is the case of GATA3-AS1 , which predicts neoadjuvant chemotherapy resistance in luminal B-like breast cancer patients with a sensitivity of 92% and specificity of 75% ( p -value = 0.0001) [ 17 ] compared to Ki-67, a clinical biomarker for neoadjuvant chemotherapy response prediction in breast cancer (sensitivity: 95.7%, specificity: 54.3%, p -value = 0.002) [ 103 ]. Another example is H19 [ 68 , 104 ] and DSCAM-AS1 [ 13 , 105 ]; not only has their biological function been described, but so has their applicability in clinical practice by establishing associations with clinical variables, such as estrogen receptor expression, which has potential application for diagnosis (sensitivity, 100.0%; specificity, 97.0%; p -value < 0.001), as well as predictive and prognostic features [ 105 ]. Furthermore, there are also studies for lncRNAs that are used as genetic signatures [ 4 , 14 , 106 ].…”

Section: The Current Use Of Lncrnas As Clinical Biomarkers In Clinica...mentioning

confidence: 99%

The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer

Arriaga-Canon

Contreras-Espinosa

Aguilar-Villanueva

et al. 2023

IJMS

View full text Add to dashboard Cite

Given their tumor-specific and stage-specific gene expression, long non-coding RNAs (lncRNAs) have demonstrated to be potential molecular biomarkers for diagnosis, prognosis, and treatment response. Particularly, the lncRNAs DSCAM-AS1 and GATA3-AS1 serve as examples of this because of their high subtype-specific expression profile in luminal B-like breast cancer. This makes them candidates to use as molecular biomarkers in clinical practice. However, lncRNA studies in breast cancer are limited in sample size and are restricted to the determination of their biological function, which represents an obstacle for its inclusion as molecular biomarkers of clinical utility. Nevertheless, due to their expression specificity among diseases, such as cancer, and their stability in body fluids, lncRNAs are promising molecular biomarkers that could improve the reliability, sensitivity, and specificity of molecular techniques used in clinical diagnosis. The development of lncRNA-based diagnostics and lncRNA-based therapeutics will be useful in routine medical practice to improve patient clinical management and quality of life.

show abstract